Unlike traditional resins, the Gore Protein A Membrane Device excels in the affinity capture of antibody-based therapies. It operates with rapid cycling and significantly higher productivity, revolutionizing the production process. By integrating the device with AGC Biologics’ monoclonal antibody production platform, manufacturers gain access to a fast-track solution for cost-efficient antibody production. Through this collaboration, AGC has demonstrated equivalency between resin-based and membrane-based technologies, ensuring comparable product quality while offering a groundbreaking alternative to the industry.
Explore how AGC Biologics and Gore’s collaboration can drive efficiency and innovation in your manufacturing processes.
The benefits of the Gore Protein A device extend across the development pipeline - from discovery to GMP-level production. In early stages, the device empowers scientists to screen molecules faster, accelerating the identification of next-generation therapies. This speed and flexibility continue through process development and clinical phases, transforming how therapies are brought to market. Additionally, the device enhances facility design by improving bioburden control and enabling flexible batch sizing. Scaling up no longer requires larger columns; instead, manufacturers can use the same device or multiple units, simplifying the process.
With its unmatched advantages, the Gore Protein A Membrane Device is poised for widespread adoption, reshaping biomanufacturing and advancing therapeutic innovation.
Watch the full video below to learn more.
